Dakota Wealth Management Has $3.46 Million Stock Holdings in Humana Inc. (NYSE:HUM)

Dakota Wealth Management grew its position in Humana Inc. (NYSE:HUM) by 27.4% in the fourth quarter, HoldingsChannel.com reports. The fund owned 7,555 shares of the insurance provider’s stock after buying an additional 1,624 shares during the period. Dakota Wealth Management’s holdings in Humana were worth $3,459,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Dorsey & Whitney Trust CO LLC increased its holdings in shares of Humana by 2.6% in the third quarter. Dorsey & Whitney Trust CO LLC now owns 817 shares of the insurance provider’s stock valued at $397,000 after purchasing an additional 21 shares during the last quarter. UMB Bank n.a. increased its position in Humana by 2.8% during the third quarter. UMB Bank n.a. now owns 805 shares of the insurance provider’s stock worth $392,000 after acquiring an additional 22 shares during the period. Vestcor Inc raised its stake in Humana by 0.3% in the 4th quarter. Vestcor Inc now owns 8,292 shares of the insurance provider’s stock worth $4,247,000 after purchasing an additional 22 shares in the last quarter. First Financial Corp IN boosted its holdings in Humana by 7.2% in the 4th quarter. First Financial Corp IN now owns 343 shares of the insurance provider’s stock valued at $157,000 after purchasing an additional 23 shares during the period. Finally, Exencial Wealth Advisors LLC grew its position in shares of Humana by 4.1% during the 4th quarter. Exencial Wealth Advisors LLC now owns 582 shares of the insurance provider’s stock worth $298,000 after purchasing an additional 23 shares in the last quarter. Institutional investors own 92.38% of the company’s stock.

Insider Buying and Selling

In related news, Director Jorge S. Mesquita purchased 545 shares of the firm’s stock in a transaction on Tuesday, February 20th. The stock was purchased at an average cost of $367.09 per share, with a total value of $200,064.05. Following the completion of the purchase, the director now owns 2,578 shares in the company, valued at approximately $946,358.02. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.29% of the stock is owned by insiders.

Humana Price Performance

Shares of HUM opened at $314.70 on Tuesday. The stock has a market cap of $37.97 billion, a PE ratio of 15.88, a PEG ratio of 1.83 and a beta of 0.45. The business has a 50-day simple moving average of $346.29 and a two-hundred day simple moving average of $427.62. The company has a quick ratio of 1.59, a current ratio of 1.59 and a debt-to-equity ratio of 0.63. Humana Inc. has a 12-month low of $299.23 and a 12-month high of $541.21.

Humana (NYSE:HUM) last announced its earnings results on Thursday, January 25th. The insurance provider reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.76 by ($0.87). The company had revenue of $26.46 billion for the quarter, compared to the consensus estimate of $25.47 billion. Humana had a return on equity of 19.44% and a net margin of 2.34%. The firm’s revenue for the quarter was up 17.9% on a year-over-year basis. During the same period in the prior year, the business earned $1.62 earnings per share. Analysts anticipate that Humana Inc. will post 16.06 earnings per share for the current fiscal year.

Humana Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, April 26th. Investors of record on Friday, March 29th will be issued a $0.885 dividend. This represents a $3.54 annualized dividend and a yield of 1.12%. The ex-dividend date of this dividend is Wednesday, March 27th. Humana’s payout ratio is presently 17.86%.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on HUM shares. Bank of America reiterated a “neutral” rating and issued a $342.00 price target (down from $470.00) on shares of Humana in a research note on Tuesday, April 2nd. Mizuho cut their target price on Humana from $550.00 to $400.00 and set a “buy” rating for the company in a research report on Friday, January 26th. Oppenheimer reaffirmed an “outperform” rating and issued a $630.00 price target on shares of Humana in a research note on Wednesday, January 17th. TD Cowen reduced their price objective on shares of Humana from $427.00 to $396.00 and set a “buy” rating on the stock in a research note on Tuesday, April 2nd. Finally, Barclays decreased their target price on shares of Humana from $356.00 to $310.00 and set an “equal weight” rating on the stock in a report on Tuesday, April 2nd. Eleven analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $465.42.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.